Human fibrinogen - Shanxi Kangbao Biological Product
Latest Information Update: 15 Jan 2016
At a glance
- Originator Shanxi Kangbao Biological Product
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Afibrinogenaemia
Most Recent Events
- 15 Jan 2016 Clinical trials in Afibrinogenaemia in China (IV) prior to January 2016 (Shanxi Kangbao Biological Product pipeline, January 2016)